Article
Alliance A071401: Phase II Trial of Focal Adhesion Kinase Inhibition in Meningiomas With Somatic NF2 Mutations.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology - 20 Jan 2023
Brastianos Priscilla K, Twohy Erin L, Gerstner Elizabeth R, Kaufmann Timothy J, Iafrate A John, Lennerz Jochen, Jeyapalan Suriya, Piccioni David E, Monga Varun, Fadul Camilo E, Schiff David, Taylor Jennie W, Chowdhary Sajeel A, Bettegowda Chetan, Ansstas George, De La Fuente Macarena, Anderson Mark D, Shonka Nicole, Damek Denise, Carrillo Jose, Kunschner-Ronan Lara J, Chaudhary Rekha, Jaeckle Kurt A, Senecal Francis M, Kaley Thomas, Morrison Tara, Thomas Alissa A, Welch Mary R, Iwamoto Fabio, Cachia David, Cohen Adam L, Vora Shivangi, Knopp Michael, Dunn Ian F, Kumthekar Priya, Sarkaria Jann, Geyer Susan, Carrero Xiomara W, Martinez-Lage Maria, Cahill Daniel P, Brown Paul D, Giannini Caterina, Santagata Sandro, Barker Frederick G, Galanis Evanthia
Abstract excerpt
PURPOSE: Patients with progressive or recurrent meningiomas have limited systemic therapy options. Focal adhesion kinase (FAK) inhibition has a synthetic lethal relationship with NF2 loss. Given the predominance of NF2 mutations in meningiomas, we evaluated the efficacy of GSK2256098, a FAK inhibitor, as part of the first genomically driven phase II study in recurrent or progressive grade 1-3 meningiomas....
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.